New combo therapy shows promise for rare lung cancer before surgery
NCT ID NCT06155279
First seen Jan 22, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether giving the immunotherapy drug pembrolizumab along with standard chemotherapy before surgery can improve outcomes for people with a rare cancer called pleural mesothelioma. The trial involves 41 adults with early-stage disease that can be surgically removed. The main goal is to see if this approach can eliminate all cancer cells in the removed tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo
Alessandria, Italy
-
Azienda Ospedaliera-Universitaria di Parma
Parma, Italy
-
Azienda Ospedaliero-Universitaria S. Anna
Ferrara, Italy
-
Centro di Riferimento Oncologico (CRO) IRCCS
Aviano, Pordenone, Italy
-
Humanitas Gavazzeni
Bergamo, Italia/Bergamo, 24125, Italy
-
IFO - Istituto Tumori Regina Elena, Roma
Roma, Italia/Roma, 00144, Italy
-
Istituto Clinico Humanitas
Rozzano, Milano, 20089, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, 35128, Italy
Conditions
Explore the condition pages connected to this study.